T. Rowe Price Associates
BCAB icon

T. Rowe Price Associates’s BioAtla BCAB Stock Holding History

T. Rowe Price Associates’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-256
Closed -$45K – 2933
2024
Q1 		$45K Buy
+256
New +$31.8K ﹤0.01% 2883
2021
Q1 		– Sell
-12,770
Closed -$21.7M – 2846
2020
Q4 		$21.7M Buy
+12,770
New +$21.3M ﹤0.01% 1209

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
SAM
Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

T. Rowe Price Associates's BCAB Position: Q2 2024 in Review

T. Rowe Price Associates sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 256 shares — an estimated $45K sold.

T. Rowe Price Associates first reported a position in BCAB in Q4 2020 and held it in 2 quarters. The position peaked at $21.7M in Q4 2020. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • T. Rowe Price Associates reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 256 BioAtla shares in Q2 2024, an estimated $45K.
  • T. Rowe Price Associates first reported a position in BioAtla in Q4 2020 and held it in 2 quarters.
  • T. Rowe Price Associates's BioAtla position peaked at $21.7M in Q4 2020.
  • 80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.